Research teams link response to Iressa to mutations in EGF receptor.
SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.
Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.
NCI blocked groups from phase III Iressa studies.
Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.
Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.
Funding opportunities listed.
April issue of Business & Regulatory Report included (8 additional pages).
Trending Stories
- CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot
- The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” - Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- Team USA’s Julie Letai competes in Milan Olympics speed skating event
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
